Li Lu, Li Lin, Cai Xianhui, Pan Zongfu
Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, People's Republic of China.
Diabetes Metab Syndr Obes. 2024 Mar 21;17:1383-1389. doi: 10.2147/DMSO.S454408. eCollection 2024.
Coronavirus disease 2019 (COVID-19)-induced new-onset diabetes has raised widespread concerns. Increased glucose concentration and insulin resistance levels were observed in the COVID-19 patients. COVID-19 patients with newly diagnosed diabetes may have worse clinical outcomes and can have serious consequences. The types and exact mechanisms of COVID-19-caused diabetes are not well understood. Understanding the direct effects of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on pancreatic beta cells and insulin target metabolism organs, such as the liver, muscle, and adipose tissues, will provide new ideas for preventing and treating the new-onset diabetes induced by COVID-19.
2019冠状病毒病（COVID-19）引发的新发糖尿病引起了广泛关注。在COVID-19患者中观察到血糖浓度和胰岛素抵抗水平升高。新诊断为糖尿病的COVID-19患者可能有更差的临床结局，并可能产生严重后果。COVID-19导致糖尿病的类型和确切机制尚不清楚。了解严重急性呼吸综合征冠状病毒2（SARS-CoV-2）对胰腺β细胞以及肝脏、肌肉和脂肪组织等胰岛素靶代谢器官的直接影响，将为预防和治疗COVID-19引发的新发糖尿病提供新思路。
